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Original article

Race and association of angiotensin converting enzyme/
angiotensin receptor blocker exposure with outcome in
heart failure
Mostafa El-Refaia, Tara Hrobowskib, Edward L. Petersonc, Karen Wellsc,
John A. Spertusd, L. Keoki Williamse and David E. Lanfeara,b,e
Purpose Angiotensin converting enzyme (ACE) inhibitors
and angiotensin receptor blockers (ARBs) have been
established as a mainstay of heart failure treatment. Current
data are limited and conflicting regarding the consistency of
ACE/ARB benefit across race groups in heart failure. This
study aims to clarify this point.
Methods This was a retrospective study of insured patients
with a documented ejection fraction of less than 50%,
hospitalized for heart failure between January 2000 and
June 2008. Pharmacy claims data were used to estimate
ACE/ARB exposure over 6-month rolling windows. The
association between ACE/ARB exposure and all-cause
hospitalization or death was assessed by proportional
hazards regression, with adjustment for baseline covariates
and b-blocker exposure. Further analyses were stratified by
race, and included an ACE/ARB T Race interaction term.
Results A total of 1095 patients met inclusion criteria
(619 African-American individuals). Median follow-up was
2.1 years. In adjusted models, ACE/ARB exposure was
associated with lower risk of death or hospitalization in both

Introduction
Despite advances in its treatment, heart failure remains a
substantial public health problem, afflicting over 500 000
Americans annually, with a US prevalence of five million
people,1 1-year mortality estimates as high as 45%2 and
annual costs in the United States of $40 billion.3 Heart
failure also displays important racial disparities with respect to outcomes and response to treatment, with AfricanAmerican patients bearing disproportionate burden.4 A
variety of explanations for these disparities have been
explored, including differences in access to care,5,6 but a
portion may be related to differential effectiveness of drug
therapies.6 This portion remains unclear in part because of
the fact that pivotal clinical trials often include insufficient
numbers of African-American patients.6,7 Neurohormonal
antagonism via angiotensin converting enzyme (ACE)
inhibitors and angiotensin receptor blockers (ARBs)
remain a cornerstone of the treatment of heart failure with
reduced ejection fraction8–12 and accordingly are a quality
metric and included in consensus guidelines.13,14
However, the data regarding whether the efficacy of
ACE/ARB differs by race are still inconclusive. A review
1558-2027 Copyright ß 2015 Wolters Kluwer Health, Inc. All rights reserved.

groups (African-Americans hazard ratio 0.47, P < 0.001;
whites hazard ratio 0.55, P < 0.001). A formal test for
interaction was consistent with similar effects in each group
(P U 0.861, b U 0.04).
Conclusion ACE/ARB exposure was equally associated
with a protective effect in preventing death or
rehospitalization among heart failure patients with systolic
dysfunction in both African-American patients and whites.
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of racial differences in blood pressure response to renin–
angiotensin–aldosterone system inhibition demonstrated
less pressure-lowering effects of these agents (compared
with thiazides and b blockers) among African-American
individuals.15 Despite this difference in effectiveness by
race in the setting of hypertension, a similar effect in
terms of clinical endpoints in heart failure patients treated with ACE/ARB remains unclear. Several studies have
suggested that ACE/ARB therapy is less effective in
African-Americans when compared with whites,16–18
but another study showed similar efficacy regardless of
race.19 We attempted to help clarify this critical point by
conducting a retrospective study of heart failure patients
examining the correlation with ACE/ARB exposure over
time with clinical outcomes and whether this association
was different in African-American compared with white
patients.

Methods
Study population

Individuals received their care through a large health
system in southeastern Michigan, which is affiliated with
DOI:10.2459/JCM.0000000000000091
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a health maintenance organization (HMO). The system’s
large administrative database was queried for this study.
Many patients are also enrolled in the affiliated HMO, and
for these patients insurance claims data are also available.
We included individuals that were more than or equal to
18 years of age with a primary hospital discharge diagnosis
of heart failure between 1 January 2000 and 30 June 2008.
The study population was limited to those that were
continuously enrolled in the HMO for at least 1 year prior
to the index hospitalization, which was defined as the first
hospitalization during the observation period, and received
their care through health system physicians. Including
only those who were enrolled in the HMO allowed access
to electronic data on all healthcare visits and prescriptions
filled whether inside or outside the health system. Our
group and others have assessed the use of primary hospital
discharge diagnosis as a claim signature for heart failure,
and it was found to be highly specific (95–100%).20,21
Follow-up continued until participants either reached
the study endpoint – that is, rehospitalization or death –
reached the end of study follow-up on 31 December 2008,
or were censored because of early disenrollment from
the HMO. The Institutional Review Board at Henry Ford
Hospital approved this study.
Data sources

The health systems’ electronic administrative databases,
Michigan Department of Community Health and the
Social Security Administration Death Master File
(DMF), were the databases used to compile the study
data. The health system administrative data provided
claims data, including coded diagnoses, procedures, and
prescription fills occurring both within and outside the
health system. Demographic data (i.e., race, sex, and date
of birth) is part of the master patient index. Race–ethnicity
was mostly self-reported, but occasionally the registering
health system employee would provide these data. A high
agreement rate between self-reported and recorded race–
ethnicity has been previously demonstrated.22 Results of
tests performed within the health system were also available. The patient’s social security number was used to
query the Michigan State Division of Vital Records and the
National Technical information Service DMF identifying
deaths. The left ventricular ejection fraction obtained from
echocardiography, nuclear stress tests, angiography, or
radionuclide pool imaging with the closest proximity to
the time of patients’ index admission was utilized in the
study. The analysis included only those individuals with
an ejection fraction less than 50%.
Pharmacy claims and angiotensin converting enzyme/
angiotensin receptor blocker exposure estimation

In order to assess the ACE/ARB exposure across the
entire class and include all the different medications in
the estimate equivalent doses of the medications were
established. This was based on the target doses prescribed for systolic heart failure or the maximum daily

dose in medications without a specific heart failure
indication from the Food and Drug Administration.
The ACE/ARB exposure estimate was calculated by
the sum of the drug-equivalent dose of medication dispensed over the 180-day window, divided by 180. Thus,
every individual had a calculated ACE/ARB exposure
estimate for each day of observation, representing his or
her average ACE/ARB exposure over the previous
6 months. The first day of estimated exposure (and hence
the first day of analysis) was 180 days after discharge from
the index hospitalization. The daily individual exposure
measures varied and when appropriate included periods
of no medication exposure. Both dose and adherence are
accounted for in this method. Similarly, a b-blocker
exposure variable was calculated and used in the analysis
to account for adherence and other medications as confounders to the benefit with ACE/ARB use.
Covariates

All multivariate models included race, sex, age, ejection
fraction, and baseline comorbid conditions (diabetes,
hypertension, atrial fibrillation, vascular disease, stroke,
preexisting heart failure, coronary disease, and renal
dysfunction) as covariates. A b-blocker exposure estimate
was also included to adjust for the benefits of this therapy
as well as to account for adherence. Adherence has been
shown to affect outcomes even in the placebo arm of
controlled trials.23 With the exception of hypertension
and diabetes, baseline characteristics were identified as
having a primary or secondary International Classification
of Diseases, Ninth Revision (ICD 9) diagnosis code or
certain disease-specific procedure codes in the year prior
to the index hospitalization. The definition of diabetes
and hypertension required two claims from any clinical
setting or at least one primary diagnosis in the baseline
year with relevant ICD 9 codes. Diabetes could also be
defined if a diabetic medication was filled at least once in
the baseline year. Along with diagnostic codes, procedure
codes related to treatment were used to define peripheral
vascular disease, end stage renal disease, coronary artery
disease, and stroke/transient ischemic attacks.
Endpoint assessment

Time to death or all-cause rehospitalization was the
composite primary endpoint. Claims data, which were
available for affiliated HMO members, were used to
identify hospital readmission. Separate analyses were
performed for all-cause death and all-cause hospitalization. Other secondary analyses were performed on
patients exposed to ACE or ARB separately. These
included all-cause hospitalization or death, death, allcause hospitalization, or heart failure hospitalization
alone. The exposure metric required a 6-month window;
therefore, the first day included in the analysis was
6 months after the index hospitalization (Fig. 1). Individuals who died or were rehospitalized in the first
6 months were excluded from the study analysis.
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Fig. 1

Results
First
exposure
estimate

The total cohort meeting inclusion criteria consisted of
476 white and 619 (56.5%) African-American individuals,
for a total of 1095 individuals. Median patient follow-up
was 2.1 years, over which time there were 478 deaths and
890 hospitalizations. African-Americans were more likely
to be younger females. They were also less likely to have
preexisting heart failure, coronary artery disease, or atrial
fibrillation (Table 1). The mean exposure estimates
were similar between groups for both ACE/ARB and b
adrenergic antagonists.

ACEi/ARB exposure
re-calculated daily

Observation period

Index
hosp.

Time
zero

1 year

6 months
Study timeline.

Statistical analysis

Chi-squared tests for categorical variables, two sample
Student’s t-tests for normally distributed continuous
variables, and two samples Mann–Whitney for continuous variables not normally distributed were used to
identify significant differences in baseline characteristics.
Multivariable proportional hazards regression models
were used to evaluate the association between ACE/
ARB exposure with the composite of all-cause rehospitalization or death. Models were also stratified by race. All
models were adjusted for sex, age, comorbidities (diabetes, hypertension, atrial fibrillation, vascular disease,
stroke, preexisting heart failure, coronary disease, and
renal dysfunction), ejection fraction, sodium level, and bblocker exposure variable. Survival curves were calculated from the Cox model evaluated at the average
covariate value and a set value of ACE/ARB exposure.
ACE/ARB exposure variable was set at the median value
or the 75th percentile to demonstrate the independent
effect of differing levels of exposure to the outcome
within each race. Secondary analyses were performed
for death, heart failure rehospitalization only, or all-cause
rehospitalization. Primary effects were considered
statistically significant for P-values <0.05. P-values
<0.1 were considered significant for interactions.24 SAS
version 9.1.3 (SAS institute, Cary, North Carolina, USA)
was used for all statistical analysis.
Table 1

ACE/ARB exposure was associated with lower risk of
death or rehospitalization in both groups (Table 2), with
hazard ratio of 0.47 (P < 0.001) and hazard ratio of 0.55
(P < 0.001) for African-Americans and whites, respectively. A formal test for race interaction was not significant
(P ¼ 0.861, b¼0.04). Figure 2 depicts the survival curves
by race and ACE/ARB exposure, based on the Cox
model. The relative protection associated with more
intense ACE/ARB exposure is represented by the space
between similar colored lines, which grossly appears to be
similarly protective across racial groups.
When examining the individual components of the
primary endpoint, our findings also appeared consistent
across race categories. In terms of all-cause mortality, ACE/
ARB exposure was associated with a protective effect in
African-Americans (hazard ratio 0.37, P < 0.001) as well as
whites (hazard ratio 0.34, P < 0.001). For time to hospitalization, ACE/ARB exposure continued to be associated
with a protective effect in both African-Americans (hazard
ratio 0.47, P ¼ 0.001) and whites (hazard ratio 0.60,
P ¼ 0.005).
We also performed a series of secondary analyses to better
characterize the relationship of these medications to
outcomes in African-Americans and whites. First, we
examined heart failure-specific rehospitalizations. Similar
to the primary analysis, this showed no significant difference in the protective association of ACE/ARB by race.
Exposure to ACE/ARB decreased the risk of heart failure
hospitalization among both white patients (hazard ratio

Baseline characteristics

Characteristic
Age (years)
Female, n (%)
Preexisting heart failure, n (%)
Diabetes, n (%)
Hypertension, n (%)
Coronary disease, n (%)
Atrial fibrillation, n (%)
PVD, n (%)
CVA, n (%)
EF
Creatinine
ACE/ARB exposure
BB exposure

African-American (n ¼ 619)

White (n ¼ 476)

P-value

64.4  14.1
273 (44%)
290 (47.1)
245 (40%)
391 (63.2)
173 (28.%)
114 (18.5%)
72 (11.6%)
85 (17.7%)
27.5  11
1.31  0.62
0.25  0.26
0.24  0.27

71.5  11.7
179 (38%)
254 (53.4)
199 (42%)
278 (58.4%)
175 (36.8%)
167 (35.1%)
68 (14.3%)
64 (13.5%)
30.1  11.4
1.29  0.51
0.28  0.28
0.25  0.27

0.001
0.030
0.037
0.457
0.109
0.002
0.001
0.192
0.891
0.001
0.27
0.1
0.74

ACE/ARB, angiotensin converting enzyme/angiotensin receptor blocker; BB, b Blocker; CVA, cerebrovascular accident; EF, ejection fraction; PVD, peripheral vascular
disease.
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Table 2

Effect of race on angiotensin converting enzyme/angiotensin receptor blocker exposure and all-cause rehospitalization or death

Outcome

African-American (HR)

P-value

White (HR)

P-value

0.47
0.37
0.47
0.48

<0.001
<0.001
0.001
0.035
b ¼ 0.04

0.55
0.34
0.60
0.66

<0.001
<0.001
0.005
0.001
0.861

All-cause death or rehospitalization (1095)
All-cause death (1095)
All-cause hospitalization (1095)
Heart failure hospitalization (1093)
ACE/ARB exposure  race interaction (all-cause death þ rehospitalization)

ACE/ARB, angiotensin converting enzyme/angiotensin receptor blocker; HR, hazard ratio. Covariates included age, sex, atrial fibrillation, diabetes, hypertension, peripheral
vascular disease, stroke, preexisting heart failure, chronic kidney disease, ejection fraction, and b-blocker exposure.

0.66, P ¼ 0.001) and African-American patients (hazard
ratio 0.48, P ¼ 0.035). Interaction testing showed no significant difference (P ¼ 0.721, b¼0.08).
We also examined ACE and ARB exposure separately, in
case a race-associated difference was class specific. Again,
we found no significant difference in the protective

association of either agent class by race (Table 3).
ACE exposure was associated with a decrease in
time to death or hospitalization in each group of similar
magnitude (white hazard ratio 0.27, P ¼ 0.001; AfricanAmerican hazard ratio 0.22, P ¼ 0.001), and interaction
was not significant (P ¼ 0.94, b¼0.02). The improved
outcomes associated with ARB exposure appeared less

Fig. 2

Time to hospitalization or death
Stratified by race and ACEi/ARB use
1.00
0.95
0.90
0.85
0.80
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0.70
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0.10
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0.00

0.25

0.50

0.75

1.00

1.25

1.50
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Years
African-American ACEi/ARB high exposure (75th percentile)
African-American ACEi/ARB low exposure (median)
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Caucasian ACEi/ARB low exposure (median)

Time to hospitalization of death: stratified by race and angiotensin converting enzyme/angiotensin receptor blocker exposure.
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Table 3

Effect of race on angiotensin converting enzyme or angiotensin receptor blocker exposure and all-cause rehospitalization and/or

death
All
HR (95% CI)
All-cause hospitalization or death
ACE (674)
0.25 (0.17, 0.36)
ARB (195)
0.67 (0.52, 0.87)
Death
ACE
0.16 (0.09, 0.29)
ARB
0.51 (0.34, 0.79)
All-cause hospitalization
ACE
0.27 (0.19, 0.39)
ARB
0.69 (0.54, 0.90)
HF hospitalization
ACE
0.28 (0.20, 0.41)
ARB
0.72 (0.55, 0.93)

White

African-American

Interaction

P-value

HR (95% CI)

P-value

HR (95% CI)

P-value

P-value

0.001
0.002

0.27 (0.16, 0.45)
0.75 (0.53, 1.08)

0.001
0.126

0.22 (0.13, 0.37)
0.62 (0.43, 0.89)

0.001
0.010

0.943
0.881

0.001
0.002

0.12 (0.05, 0.29)
0.56 (0.31, 1.02)

0.001
0.058

0.21 (0.009, 0.47)
0.48 (0.26, 0.90)

0.001
0.021

0.541
0.775

0.001
0.005

0.31 (0.18, 0.52)
0.78 (0.54, 1.13)

0.001
0.196

0.22 (0.13, 0.38)
0.64 (0.44, 0.91)

0.001
0.014

0.818
0.950

0.001
0.013

0.35 (0.21, 0.60)
0.83 (0.57, 1.21)

0.001
0.329

0.23 (0.13, 0.39)
0.65 (0.45, 0.94)

0.001
0.021

0.691
0.970

Covariates included age, sex, atrial fibrillation, diabetes, hypertension, peripheral vascular disease, stroke, preexisting heart failure, chronic kidney disease, ejection fraction,
and b-blocker exposure.

robust (relative to ACE exposure), however, this
represented a smaller subgroup (n ¼ 195). Regardless,
we found no evidence of a difference across race
(P ¼ 0.88, b¼0.04).

Discussion
Our data help clarify the questions that still surround the
issue of racial differences in the efficacy of heart failure
therapies, specifically related to ACE inhibitors and
ARBs. In this adequately powered, retrospective study,
ACE/ARB exposure was associated with a similar protective effect in both whites and African-Americans with
systolic heart failure. The effect of ACE/ARB exposure
on death or rehospitalization and death alone was both
significant and similar for both groups.
Previous analyses of other cohorts have demonstrated
conflicting results. A retrospective analysis of the Studies
of Left Ventricular Dysfunction (SOLVD) cohort
(n ¼ 1196; blacks ¼ 800) suggested a differing effect of
enalapril on preventing hospitalization between whites
and African-Americans. Although placebo-matched
white patients had a decrease in hospitalization when
given enalapril (relative risk 0.51, confidence interval
0.37–0.7), a similar effect was absent in the AfricanAmerican group.18 However, a subsequent meta-analysis
of the SOLVD trial (n ¼ 6797; blacks ¼ 800) showed no
difference in mortality between blacks and whites with
the prescription of enalapril.25 Another analysis (n ¼ 4054;
blacks ¼ 403) examining the progression to symptomatic
heart failure also failed to show a significant difference
between races.19 Analysis of the Veterans Affairs Vasodilator-Heart Failure Trials (V-HeFT II) trial (n ¼ 804;
blacks ¼ 215) suggested that there is a difference in the
survival benefit of ACE inhibitors between whites and
blacks.16 The notable benefit was seen most clearly in
whites (P < 0.02), and a race interaction variable reached
statistical significance with (P ¼ 0.09) in that study.
Although this disagrees with our study, these data

are limited by the relatively small number of AfricanAmericans and the fact that only male patients were
included in the study. In contrast, our study population
was larger, including three times the number of selfidentified African-Americans, included both sexes, and
had a more equitable race distribution.
Furthermore, our methodology allows a more granular
accounting of medication exposure, as well as accounting
for medication adherence, which can differ with selfidentified race. Thus, we are able to clearly show significantly reduced mortality and hospitalization associated
with ACE or ARB exposure among African-Americans
with systolic heart failure, who have been underrepresented in heart failure trials. Although the retrospective
nature of our study prevents it from defining the absolute
benefit of these medications in African-Americans, our
data clearly support their effectiveness in this setting.
Moreover, the retrospective nature does not mitigate the
validity in terms of comparing effectiveness between
African-American and white patients, which our data
clearly indicate is similar in magnitude, which should
put to rest any persisting concerns that ACE inhibitors are
less effective or suboptimal treatment for AfricanAmericans with heart failure.
Our study should be interpreted bearing in mind some
potential limitations. As mentioned above, retrospective
studies have inherent limitations, including potential
selection bias or unidentified confounding factors. Some
variables of possible interest were missing from our
administrative data, including blood pressure and diuretic
use. Despite these the primary comparison by race should
be robust to most such factors, and we have diligently
tried to adjust for potential confounding factors. The fact
that our data are derived from a single center study may
limit external validity, although our diverse study population reflects well the greater metropolitan population of
our region.26 Given the use of administrative data, diagnostic misclassification may have occurred, but when
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evaluating heart failure as a primary discharge diagnosis,
our group and others have found that ICD 9 codes were
95–100% specific in meeting Framingham heart failure
Criteria.20 Finally, the ACE/ARB exposure variable
included a variety of medications within the classes
and an estimated equivalent dose calculation which
may be imperfect. However, one might expect that this
would likely affect both races equally thus not impacting
the racial effectiveness comparison.

7
8

9

10

11

Conclusion
ACE/ARB exposure is associated with a similarly significant protective effect in both white and AfricanAmerican patients with systolic heart failure, with very
similar magnitude of effect in both groups. This supports
the continued usage of these medication classes in AfricanAmericans and alleviates any concern for decreased
efficacy in African-Americans with heart failure.
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